Trial Profile
IL-4 & Insulin Resistance in Patients With Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 29 Feb 2024
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- 22 Feb 2024 Status changed from suspended to completed.
- 01 Jun 2023 Planned End Date changed from 1 May 2023 to 1 May 2024.
- 01 Jun 2023 Planned primary completion date changed from 1 May 2023 to 1 May 2024.